Blogs
France’s New ATU Process: Why only truly innovative therapies should now apply
By Nicola Allen, Associate Director & Andrea Bernardini, Analyst Email: nallen@partners4access.com or abernardini@partners4access.com The French Authorisation for Temporary Use (ATU) was originally established in 1994
India’s new draft national policy for rare disease and the road to accessing gene therapies
By Ciaran Cassidy, Snr Analyst Email: ccassidy@partners4access.com With one of the fastest-growing economies and the second largest population in the world India is a market
4 key trends changing the access landscape through to 2025
By Jens Leutloff, Senior Consultant Email: jleutloff@partners4access.com Partners4Access asked payer experts from France, Germany, Italy, Spain, and the Nordics what the key trends are for
HTA and pricing update: Recent moves on drug cost-control by European payers
By Chloe Sheppard, Analyst Email: csheppard@partners4access.com The issue of affordability and access to medicines has been brought to the forefront of policymakers’ and payers’ attention
Trump finally signs executive order on Medicare drug pricing but will anything change on the ground?
By Max Rex, Consultant Email: mrex@partners4access.com After years of rhetoric about drug pricing, President Trump signed an executive order on Sunday 13th September which aims
Driving patient access for treatments targeting rare genetic disorders in the Middle East
By Ciaran Cassidy, S Analyst Email: ccassidy@partners4access.com At the World Orphan Drug Conference (WODC) this year Dr Maryam Matar presented on the success of the
Under the microscope: Orphan Drug incentives in Europe
By Chloe Sheppard, Analyst Email: csheppard@partners4access.com The European Commission is imminently expected to publish a report evaluating the pros and cons of the EU Orphan
France to place restrictions on Nominative ATU
By Erfan Akbraian, Analyst Email: eakbraian@partners4access.com France’s National Agency for the Safety of Medicines and Health Products (ANSM)1 governs the early access program called autorisation
Zolgensma’s ‘Day One’ access scheme – can Novartis’s early access plan succeed?
By Max Rex, Associate Consultant Email: mrex@partners4access.com Zolgensma, Novartis’s blockbuster gene therapy for the treatment of spinal muscular atrophy (SMA), was officially given the green
